Prevalence of Kidney Cancer in Attendees for Combined Lung and Kidney Cancer Screening by Computed Tomography Scanning.
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Department of Surgery
https://doi.org/10.1016/j.euo.2025.07.004
Department of Surgery
https://doi.org/10.1016/j.euo.2025.07.004
Abstract
Description
Kidney cancer (KC) screening may be facilitated by targeting individuals at a higher risk and combining with other screening programmes. Previous estimates of the prevalence of screen-detected KC are outdated and do not enable an accurate assessment in a high-risk group. The Yorkshire Kidney Screening Trial (YKST) is a unique study of the feasibility of adding KC screening via an abdominal noncontrast computed tomography (CT) scan to the thoracic low-dose CT within a targeted lung cancer screening trial in ever smokers (Yorkshire Lung Screening Trial; YLST). Seventeen histologically confirmed KC cases were detected on thoracic CT in YLST (N = 6650; prevalence 0.26%; 95% confidence interval [CI] 0.15-0.41%), which has implications for future service planning to accommodate the investigation and treatment of screen-detected KC patients following the national adoption of lung cancer screening. Adding abdominal CT in YKST (n = 4019) identified an additional ten histologically confirmed KC patients (prevalence 0.25%; 95% CI 0.12-0.46%). In summary, using data from YKST, we report the first contemporary estimates of the prevalence of KC in high-risk individuals, key data required to plan future prospective screening studies.
YKST was funded by Yorkshire Cancer Research grant number L403C. Grant D. Stewart is supported by The Mark Foundation for Cancer Research, the Cancer Research UK Cambridge Centre (C9685/A25177 and CTRQQR-2021\100012), and NIHR Cambridge Biomedical Research Centre (NIHR203312). Philip A.J. Crosbie is supported by the Manchester National Institute for Health Research Manchester Biomedical Research Centre (IS-BRC- 1215-20007). Juliet A. Usher-Smith is supported by an NIHR Advanced Fellowship (NIHR300861). Sh Rossi is funded by a university of Cambridge ACL.
YKST was funded by Yorkshire Cancer Research grant number L403C. Grant D. Stewart is supported by The Mark Foundation for Cancer Research, the Cancer Research UK Cambridge Centre (C9685/A25177 and CTRQQR-2021\100012), and NIHR Cambridge Biomedical Research Centre (NIHR203312). Philip A.J. Crosbie is supported by the Manchester National Institute for Health Research Manchester Biomedical Research Centre (IS-BRC- 1215-20007). Juliet A. Usher-Smith is supported by an NIHR Advanced Fellowship (NIHR300861). Sh Rossi is funded by a university of Cambridge ACL.